Diabetes Research and Clinical Practice
Volume 74, Issue 2, Supplement , Pages S12-S16 , 30 November 2006

Type 2 diabetes mellitus as inflammatory disease

References 

  1. Cone JB. Inflammation. Am J Surg. 2001;182:558–562
  2. Kolb H, Mandrup-Poulsen T. An immune origin of type 2 diabetes?. Diabetologia. 2005;48:1038–1050
  3. Ford ES. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis. 2003;168:351–358
  4. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327–334
  5. Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C, Tatranni PA. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002;51:455–461
  6. Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction. Arterioscler Thromb Vasc Biol. 1999;19:972–978
  7. Festa A, D’Agostiono R, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome; The Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42–47
  8. Marti A, Marcos A, Martinez JA. Obesity and immune function relationships. Obesity Rev. 2001;2:131–140
  9. Tataranni PA, Ortega E. Does an adipokine-induced activation of the immune system mediate the effect of overnutrition on type 2 diabetes?. Diabetes. 2005;54:917–927
  10. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of Type 2 diabetes. Diabetes Care. 2004;27:813–823
  11. Temelkova-Kurktschiev T, Henkel E, Koehler C, Karrei K, Hanefeld M. Suclinical inflammation in newly detected type II diabetes and impaired glucose tolerance. Diabetologia. 2002;45:151
  12. Saito I, Folsom AR, Brancati FL, Duncan BB, Chambless LE, McGovern PG. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Ann Int Med. 2000;133:81–91
  13. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet. 1999;353:1649–1652
  14. Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, et al. Low-grade systemic inflammtion and the development of type 2 diabetes. The Atherosclerosis Risk in Communities Study. Diabetes. 2003;52:1799–1805
  15. Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, et al. The relationship of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes. 2001;50:2384–2389
  16. Snijder MB, Dekker JM, Visser M, Steuhouwer CDA, van Hinsberg VWM, Bouter LM, et al. C-reactive protein and diabetes mellitus type 2. Diabetologia. 2001;44:115A
  17. Thorand B, Lowel H, Schneider A, Kolb H, Frohlich M, Koenig W. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study. Arch Intern Med. 2003;163:93–99
  18. Ford ES. Leucocyte count, erythrocyte sedimentation rate, and diabetes incidence in a national sample of US adults. Am J Epidemiol. 2002;155:57–64
  19. Nakanishi N, Yoshida H, Matsuo Y, Suzuki K, Tatara K. White blood cell count and the risk of impaired fasting glucose or type II diabetes mellitus in middle-aged Japanese men. Diabetologia. 2002;45:42–48
  20. The Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986
  21. Turner RC, Millns HA, Neil HA, Stratton IM, Manley SE, Matthews DR, et al. For the UKPDS Study Group Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ. 1998;316:823–833
  22. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans. Role of oxidative stress. Circulation. 2002;106:2067–2072
  23. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol. 2004;24:816–823
  24. Brownlee M. The pathobiology of diabetic complications; a unifying mechanism. Diabetes. 2005;54:1615–1625
  25. Vlassara H. Recent progress in advanced glycation and products and diabetic complications. Diabetes. 1997;46(Suppl. 2):S19–S25
  26. Marshall S, Rumberger JM. The hexosamine signaling pathway: role in glucose sensing and intergration of cellular metabolism. In:  Walker M,  Butler Q,  Rizza RA editor. The diabetes annual/13. Elsevier Science; 2000;p. 97–102
  27. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404:787–790
  28. Wierusz-Wysocka B, Wysocki H, Siekierka H, Wykrętowicz A, Szczepanik A, Klimas R. Evidence of polymorphonuclear neutrophils (PMN) activation in patients with diabetes mellitus. J Leuk Biol. 1987;42:519–524
  29. Zozuliñska D, Wierusz-Wysocka B, Wysocki H, Majchrzak A, Wykretowicz A. The influence of IDDM duration on superoxide anions and hydrogen peroxide production by polymorphonuclear neutrophils. Diab Res Clin Pract. 1996;33:139–144
  30. Schmid-Schönbein GW. The damaging potential of leukocyte activation in the microcirculation. Angiology. 1993;44:45–56
  31. Adams DH, Shaw S. Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet. 1994;343:831–836
  32. Grykiel K, Zozulińska D, Kostrzewa A, Wiktorowicz K, Wierusz-Wysocka B. Increased expression of polymorphonuclear neutrophil surface receptors and serum L-selectin concentration in type 1 diabetic patients. Diab Res Clin Pract. 2000;S349
  33. Zozulińska D, Pisarczyk-Wiza D, Wierusz-Wysocka B. The influence of postprandial state on polymorphonuclear function in Type 1 diabetic patients. Prog Med Res. 2004;2:27–31http://www.progmedres.com
  34. Wheeler JG, Mussolino ME, Gillum RF, Danesh J. Association between differential leucocyte count and incident coronary heart disease: 1764 incident cases from seven prospective studies of 30374 individuals. Eur Heart J. 2004;25:1287–1293
  35. Piłaciński S, Uruski P, Sporna A, Pelczar A, Dudziak J, Kosikowski P, et al. Markers of inflammation as risk factors for diabetic microangiopathy. Diab Polska. 2005;12:117
  36. Schulze MB, Hoffmann K, Manson JE, Willett WC, Meigs JB, Weikert C, et al. Dietary pattern, inflammation, and incidence of type 2 diabetes in women. Am J Clin Nutr. 2005;82:675–684
  37. Laufs U, Wassmann S, Czech T, Münzel T, Eisehauer M, Böhm M, et al. Physical inactivity increases oxidative stress, endothelial dysfunction, and atherosclerosis. Arterioscler Thromb Vasc Biol. 2005;25:809–814
  38. Van Oosrom AJ, van Wijk JP, Castro M. Cabezas, Lipaemia, inflammation and atherosclerosis: novel opportunities in the understanding and treatment of atherosclerosis. Drugs. 2004;64(Suppl. 2):19–41
  39. Li JJ, Fang CH, Hui RT. Is hypertension an inflammatory disease?. Med Hypotheses. 2005;64:236–246
  40. Giannopolou I, Fernhall B, Carhart R, Weinstock RS, Baynard T, Figureoa A, et al. Effects of diet and/or exercise on the adipocytokines and inflammatory cytokine levels of postmenopausal women with type 2 diabetes. Metabolism. 2005;54:866–875
  41. Kasapis C, Thompson PD. The effects of physical activity on serum C-reactive protein and inflammatory markers. J Am Coll Cardiol. 2005;45:1563–1569
  42. Esposito K, Pontiloo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomised trial. JAMA. 2003;289:1799–1804
  43. Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by provastatin. Lancet. 1999;353:983–984
  44. Hundal RS, Petersen KF, Mayerson AB, Randhava PS, Inzucchi S, Shoelsen SE, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest. 2002;109:1321–1326
  45. Nesto R. C-reactive proteins, its role in inflammation, type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones. Diab Med. 2004;21:810–817
  46. HOPE/HOPE-TOO Study Investigators . Long-term effects of ramipril on cardiovascular events and on diabetes. Circulation. 2005;112:1339–1346
  47. Sierra C, de-la Sierra A. Atihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers. Curr Opin Nephrol Hypertens. 2005;14:435–441

PII: S0168-8227(06)00255-5

doi: 10.1016/j.diabres.2006.06.007

Diabetes Research and Clinical Practice
Volume 74, Issue 2, Supplement , Pages S12-S16 , 30 November 2006

Article Tools